NCT02873975 2022-10-21
A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency
Dana-Farber Cancer Institute
Phase 2 Completed
Dana-Farber Cancer Institute
Memorial Sloan Kettering Cancer Center